What it's for (Indications)
- Piroxicam-beta-cyclodextrin (e.
- g.
- , Peldin) is indicated for the symptomatic treatment of acute and chronic inflammatory conditions requiring rapid onset of action and significant pain relief.
- This includes, but is not limited to, osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute musculoskeletal disorders, and acute gouty arthritis.
- Its formulation with beta-cyclodextrin is specifically designed to enhance the dissolution rate and absorption of piroxicam, leading to a faster onset of analgesic and anti-inflammatory effects compared to conventional piroxicam.
- Clinicians should consider the patient's individual risk factors for gastrointestinal and cardiovascular adverse events before initiating therapy, and treatment duration should be as short as possible at the lowest effective dose to mitigate potential risks.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For adults, the typical recommended dosage of piroxicam-beta-cyclodextrin is 20 mg taken orally once daily. This formulation is designed for rapid absorption, providing a quicker onset of action. In some acute conditions, an initial loading dose may be considered by a prescribing physician, but adherence to the 20 mg daily regimen is generally paramount for sustained efficacy and safety. Dosage adjustments may be necessary in patients with renal or hepatic impairment, though the drug is generally not recommended in severe cases. Given the potential for serious adverse events, the lowest effective dose should always be used for the shortest possible duration consistent with treatment goals. Patients should be advised to take the medication with food or milk to minimize gastrointestinal discomfort, although the beta-cyclodextrin complexation aims to improve gastric tolerability to some extent. |
Safety & Warnings
Common Side Effects
- Common side effects associated with piroxicam-beta-cyclodextrin are similar to those of other NSAIDs and include gastrointestinal disturbances such as dyspepsia, nausea, abdominal pain, diarrhea, and constipation; more serious GI events like ulceration and bleeding are also possible (see Black Box Warning).
- Central nervous system effects can include headache, dizziness, vertigo, and somnolence.
- Dermatological reactions such as rash, pruritus, and photosensitivity may occur, with rare but severe skin reactions like Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) also reported.
- Renal adverse effects include fluid retention, edema, increased blood pressure, and acute kidney injury.
- Cardiovascular risks include hypertension and exacerbation of heart failure.
- Hematologic effects such as anemia, prolonged bleeding time, and thrombocytopenia can also manifest.
- Hepatic effects, including elevated liver enzymes, have been reported, with rare instances of severe liver injury.
- Patients should be counselled to report any unusual symptoms promptly.
Serious Warnings
- Black Box Warning: **CARDIOVASCULAR THROMBOTIC EVENTS:** Non-steroidal anti-inflammatory drugs (NSAIDs), including piroxicam-beta-cyclodextrin, increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use and in patients with pre-existing cardiovascular disease or risk factors for cardiovascular disease. Patients with known cardiovascular disease may be at greater risk. Piroxicam-beta-cyclodextrin is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. **GASTROINTESTINAL RISK:** NSAIDs, including piroxicam-beta-cyclodextrin, cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or gastrointestinal bleeding are at greater risk for serious gastrointestinal events. Therefore, careful consideration of the risk-benefit profile is imperative before prescribing.
- Piroxicam-beta-cyclodextrin should be used with caution in patients with a history of hypertension, congestive heart failure, or conditions predisposing to fluid retention and edema, as NSAIDs can exacerbate these conditions.
- Renal papillary necrosis and other renal injury have been observed with chronic NSAID use, necessitating careful monitoring of renal function, particularly in elderly patients or those with pre-existing renal impairment, heart failure, or liver dysfunction, and those on diuretics or ACE inhibitors.
- Anaphylactoid reactions can occur, even without prior exposure.
- NSAIDs, including piroxicam, can cause serious skin adverse reactions such as exfoliative dermatitis, SJS, and TEN, which can be fatal.
- Piroxicam may prolong bleeding time and inhibit platelet aggregation; patients with coagulation disorders or on anticoagulant therapy require close monitoring.
- Hepatic reactions, including jaundice and fatal fulminant hepatitis, have occurred.
- It is not recommended for use in the third trimester of pregnancy due to risks to the fetus and difficulties in labor.
- Patients should be advised to avoid concomitant use with other NSAIDs.
How it Works (Mechanism of Action)
Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class, functioning primarily through the non-selective inhibition of cyclooxygenase enzymes, specifically COX-1 and COX-2. This inhibition leads to a reduction in the synthesis of prostaglandins, which are key mediators of inflammation, pain, and fever. By attenuating prostaglandin production, piroxicam exerts its anti-inflammatory, analgesic, and antipyretic effects. The beta-cyclodextrin component in this formulation acts as a molecular encapsulating agent. It forms an inclusion complex with piroxicam, significantly enhancing its aqueous solubility and dissolution rate. This improved solubility and faster dissolution allow for more rapid absorption of piroxicam from the gastrointestinal tract, resulting in quicker attainment of therapeutic plasma concentrations and a more rapid onset of pain relief and anti-inflammatory action compared to conventional piroxicam formulations.